RACTIGEN THERAPEUTICS
Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.
RACTIGEN THERAPEUTICS
Social Links:
Industry:
Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Nantong, Jiangsu, China
Country:
China
Website Url:
http://www.ractigen.com
Total Employee:
1+
Status:
Active
Contact:
(+86) 513-81996959
Email Addresses:
[email protected]
Total Funding:
46.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Domain Not Resolving
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
KBP Biosciences
A multinational clinical stage biotechnology company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Current Employees Featured
Founder
Investors List
LC Ventures
LC Ventures investment in Series A - Ractigen Therapeutics
SDIC Venture Capital
SDIC Venture Capital investment in Series A - Ractigen Therapeutics
China Singapore Suzhou Industrial Park Ventures
China Singapore Suzhou Industrial Park Ventures investment in Series A - Ractigen Therapeutics
Eisai
Eisai investment in Series A - Ractigen Therapeutics
Xianghe Capital
Xianghe Capital investment in Series A - Ractigen Therapeutics
Boyi Fund
Boyi Fund investment in Series A - Ractigen Therapeutics
GL Ventures
GL Ventures investment in Series A - Ractigen Therapeutics
Longmen Capital
Longmen Capital investment in Series A - Ractigen Therapeutics
Official Site Inspections
http://www.ractigen.com
- Host name: 99.220.221.35.bc.googleusercontent.com
- IP address: 35.221.220.99
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Ractigen Therapeutics"
Insufficient Gene Expression - Ractigen Therapeutics
Ractigen Therapeutics, a clinical-stage pharmaceutical company, specializes in developing pioneering therapies aimed at enhancing the expression of therapeutic genes within diseased …See details»
Ractigen Therapeutics
Nov 19, 2024 · RNAa (RNA activation) is a platform technology to selectively turn genes on by using short duplex RNA known as small activating RNA (saRNA). RNAa is among the limited …See details»
Ractigen Therapeutics Management Team, and Boards
Our leadership comprises a unified team of experts in RNA research and drug development, including the pioneers of RNAa technology, specialists in nucleic acid chemistry, biotech …See details»
Ractigen Therapeutics - Crunchbase Company Profile …
Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells.See details»
Ractigen Therapeutics - LinkedIn
Ractigen Therapeutics is a clinical stage biotech company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in...See details»
Ractigen Therapeutics - Leadership Team - The Org
The Leadership Team at Ractigen Therapeutics is responsible for setting the strategic direction of the company, overseeing research and development initiatives, ensuring regulatory …See details»
Ractigen Therapeutics closes an additional $30 million in Series A+ ...
NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling $30 million …See details»
Ractigen Therapeutics Announces FDA Approval for RAG-01, a …
Apr 26, 2024 · Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) …See details»
Ractigen Therapeutics Announces FDA Approval for RAG-01, a …
Apr 26, 2024 · RAG-01 is a pioneering therapy in bladder cancer treatment, representing the first of its kind to specifically target and activate the p21 tumor suppressor gene. This gene is …See details»
Ractigen Therapeutics Announces FDA Orphan Drug Designation …
Nov 20, 2024 · RAG-21 is an siRNA therapy specifically designed to target FUS -ALS, one of the most aggressive subtype of ALS. By leveraging RNA interference (RNAi), RAG-21 safely and …See details»
Ractigen Therapeutics Receives FDA Orphan Drug Designation for …
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug …See details»
Ractigen Announces U.S. FDA Rare Pediatric Disease Designation …
Jul 25, 2024 · RAG-18 could represent a novel and translatable therapeutic strategy for DMD and Becker Muscular Dystrophy (BMD) caused by any mutation of the DMD gene.See details»
Envision - Ractigen Therapeutics
Nov 19, 2024 · Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital Ractigen Therapeutics, a leading …See details»
Our Pipeline - Ractigen Therapeutics
Oct 11, 2017 · Ractigen’s pipeline includes internal and co-development projects that explore the boundaries of our technology and push for the next generation of RNAa therapeutics. Spinal …See details»
Ractigen Therapeutics closes an additional $30 million in Series A+ ...
NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling $30 million …See details»
Ractigen Therapeutics Announces FDA Orphan Drug Designation …
Nov 19, 2024 · NANTONG and SUZHOU, China, Nov. 19, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today …See details»
Ractigen Therapeutics Secures FDA Fast Track Designation for …
SUZHOU, China, May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, …See details»
Ractigen Therapeutics Announces FDA Orphan Drug Designation …
Nov 19, 2024 · RAG-21 is an siRNA therapy specifically designed to target FUS -ALS, one of the most aggressive subtype of ALS. By leveraging RNA interference (RNAi), RAG-21 safely and …See details»
News & Events - Ractigen Therapeutics
May 21, 2024 · Ractigen Therapeutics News and Events - Stay Informed with Industry Insights and Follow Our ProgressSee details»
Ractigen Announces Positive Clinical Data for RAG-17 in ALS …
Sep 10, 2024 · NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing …See details»